{"Welcome.html": {"id": "Welcome.html", "text": "Welcome", "displayed_text": "Welcome"}, "Task.html": {"id": "Task.html", "text": "Task", "displayed_text": "Task"}, "Causality.html": {"id": "Causality.html", "text": "Causality", "displayed_text": "Causality"}, "Causality Examples.html": {"id": "Causality Examples.html", "text": "Causality Examples", "displayed_text": "Causality Examples"}, "Navigation.html": {"id": "Navigation.html", "text": "Navigation", "displayed_text": "Navigation"}, "Consent.html": {"id": "Consent.html", "text": "Consent", "displayed_text": "Consent"}, "Medicine_tweet_24_r": {"DOI": "10.1001/jamainternmed.2018.2259", "id": "Medicine_tweet_24_r", "News Finding": "Tamulosin is often used in patients with kidney stones in the hope it will speed stone passage.  This RCT shows it is ineffective.  ", "Paper Finding": "Meaning For emergency department patients who present with renal colic owing to ureteral stones smaller than 9 mm, tamsulosin does not appear to promote stone passage.", "News Context": "Tamulosin is often used in patients with kidney stones in the hope it will speed stone passage.  This RCT shows it is ineffective.  ", "Paper Context": "Findings In this randomized clinical trial of 512 adults, the proportion achieving ureteral stone expulsion by 28 days was 50% with tamsulosin vs 47% with placebo, a nonsignificant difference. Meaning For emergency department patients who present with renal colic owing to ureteral stones smaller than 9 mm, tamsulosin does not appear to promote stone passage. In the 11 cases for which this algorithm did not yield a clear result, the CT scans were individually reviewed and a consensus was reached.", "scores": "[5.0, 4.0, 5.0]", "field": "Medicine", "split": "train", "final_score": 4.666666666666667, "source": "tweets", "News URL": "1008762116805808134", "text": "['<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Tamulosin is often used in patients with kidney stones in the hope it will speed stone passage.  This RCT shows it is ineffective.  \"><b>Finding:</b></span> Tamulosin is often used in patients with kidney stones in the hope it will speed stone passage.  This RCT shows it is ineffective.  ']", "displayed_text": "<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Tamulosin is often used in patients with kidney stones in the hope it will speed stone passage.  This RCT shows it is ineffective.  \"><b>Finding:</b></span> Tamulosin is often used in patients with kidney stones in the hope it will speed stone passage.  This RCT shows it is ineffective.  "}, "Medicine_tweet_24_p": {"DOI": "10.1001/jamainternmed.2018.2259", "id": "Medicine_tweet_24_p", "News Finding": "Tamulosin is often used in patients with kidney stones in the hope it will speed stone passage.  This RCT shows it is ineffective.  ", "Paper Finding": "Meaning For emergency department patients who present with renal colic owing to ureteral stones smaller than 9 mm, tamsulosin does not appear to promote stone passage.", "News Context": "Tamulosin is often used in patients with kidney stones in the hope it will speed stone passage.  This RCT shows it is ineffective.  ", "Paper Context": "Findings In this randomized clinical trial of 512 adults, the proportion achieving ureteral stone expulsion by 28 days was 50% with tamsulosin vs 47% with placebo, a nonsignificant difference. Meaning For emergency department patients who present with renal colic owing to ureteral stones smaller than 9 mm, tamsulosin does not appear to promote stone passage. In the 11 cases for which this algorithm did not yield a clear result, the CT scans were individually reviewed and a consensus was reached.", "scores": "[5.0, 4.0, 5.0]", "field": "Medicine", "split": "train", "final_score": 4.666666666666667, "source": "tweets", "News URL": "1008762116805808134", "text": "['<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Findings In this randomized clinical trial of 512 adults, the proportion achieving ureteral stone expulsion by 28 days was 50% with tamsulosin vs 47% with placebo, a nonsignificant difference. Meaning For emergency department patients who present with renal colic owing to ureteral stones smaller than 9 mm, tamsulosin does not appear to promote stone passage. In the 11 cases for which this algorithm did not yield a clear result, the CT scans were individually reviewed and a consensus was reached.\"><b>Finding:</b></span> Meaning For emergency department patients who present with renal colic owing to ureteral stones smaller than 9 mm, tamsulosin does not appear to promote stone passage.']", "displayed_text": "<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Findings In this randomized clinical trial of 512 adults, the proportion achieving ureteral stone expulsion by 28 days was 50% with tamsulosin vs 47% with placebo, a nonsignificant difference. Meaning For emergency department patients who present with renal colic owing to ureteral stones smaller than 9 mm, tamsulosin does not appear to promote stone passage. In the 11 cases for which this algorithm did not yield a clear result, the CT scans were individually reviewed and a consensus was reached.\"><b>Finding:</b></span> Meaning For emergency department patients who present with renal colic owing to ureteral stones smaller than 9 mm, tamsulosin does not appear to promote stone passage."}, "Medicine_402_r": {"DOI": "10.1007/s10484-015-9286-9", "id": "Medicine_402_r", "News Finding": "\"Because evidence shows that low HRV is a potential risk factor for sexual dysfunction, physicians have a simple, low-cost and nonintrusive method to measure a woman's risk for sexual dysfunction,\" said Stanton.", "Paper Finding": "In conclusion, low HRV may be a risk factor for female sexual arousal dysfunction and overall sexual dysfunction.", "News Context": "With recent support from the Food and Drug Administration on what could be the first-ever approved drug for the treatment of female sexual dysfunction, the researchers believe that HRV could be used as an index of drug-related changes in sexual function. \"Because evidence shows that low HRV is a potential risk factor for sexual dysfunction, physicians have a simple, low-cost and nonintrusive method to measure a woman's risk for sexual dysfunction,\" said Stanton. \"It makes it easier to talk about something a little bit more private and get women the help that they need.\"", "Paper Context": "Women with below average HRV were significantly more likely to report sexual arousal dysfunction (p \\ .001) and overall sexual dysfunction (p \\ .001) than both women with average HRV and women with above average HRV. In conclusion, low HRV may be a risk factor for female sexual arousal dysfunction and overall sexual dysfunction. Given these findings, it is reasonable to expect ANS activity (indexed by HRV) may be related to women's self-reported, real-life sexual arousal function outside of the laboratory.", "scores": "[4.0, 5.0, 4.0, 4.0, 4.0]", "field": "Medicine", "split": "train", "final_score": 4.2, "source": "news", "News URL": "http://www.newswise.com/articles/study-links-heartbeat-to-female-libido", "text": "['<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: With recent support from the Food and Drug Administration on what could be the first-ever approved drug for the treatment of female sexual dysfunction, the researchers believe that HRV could be used as an index of drug-related changes in sexual function. \"Because evidence shows that low HRV is a potential risk factor for sexual dysfunction, physicians have a simple, low-cost and nonintrusive method to measure a woman\\'s risk for sexual dysfunction,\" said Stanton. \"It makes it easier to talk about something a little bit more private and get women the help that they need.\"\"><b>Finding:</b></span> \"Because evidence shows that low HRV is a potential risk factor for sexual dysfunction, physicians have a simple, low-cost and nonintrusive method to measure a woman\\'s risk for sexual dysfunction,\" said Stanton.']", "displayed_text": "<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: With recent support from the Food and Drug Administration on what could be the first-ever approved drug for the treatment of female sexual dysfunction, the researchers believe that HRV could be used as an index of drug-related changes in sexual function. \"Because evidence shows that low HRV is a potential risk factor for sexual dysfunction, physicians have a simple, low-cost and nonintrusive method to measure a woman's risk for sexual dysfunction,\" said Stanton. \"It makes it easier to talk about something a little bit more private and get women the help that they need.\"\"><b>Finding:</b></span> \"Because evidence shows that low HRV is a potential risk factor for sexual dysfunction, physicians have a simple, low-cost and nonintrusive method to measure a woman's risk for sexual dysfunction,\" said Stanton."}, "Medicine_402_p": {"DOI": "10.1007/s10484-015-9286-9", "id": "Medicine_402_p", "News Finding": "\"Because evidence shows that low HRV is a potential risk factor for sexual dysfunction, physicians have a simple, low-cost and nonintrusive method to measure a woman's risk for sexual dysfunction,\" said Stanton.", "Paper Finding": "In conclusion, low HRV may be a risk factor for female sexual arousal dysfunction and overall sexual dysfunction.", "News Context": "With recent support from the Food and Drug Administration on what could be the first-ever approved drug for the treatment of female sexual dysfunction, the researchers believe that HRV could be used as an index of drug-related changes in sexual function. \"Because evidence shows that low HRV is a potential risk factor for sexual dysfunction, physicians have a simple, low-cost and nonintrusive method to measure a woman's risk for sexual dysfunction,\" said Stanton. \"It makes it easier to talk about something a little bit more private and get women the help that they need.\"", "Paper Context": "Women with below average HRV were significantly more likely to report sexual arousal dysfunction (p \\ .001) and overall sexual dysfunction (p \\ .001) than both women with average HRV and women with above average HRV. In conclusion, low HRV may be a risk factor for female sexual arousal dysfunction and overall sexual dysfunction. Given these findings, it is reasonable to expect ANS activity (indexed by HRV) may be related to women's self-reported, real-life sexual arousal function outside of the laboratory.", "scores": "[4.0, 5.0, 4.0, 4.0, 4.0]", "field": "Medicine", "split": "train", "final_score": 4.2, "source": "news", "News URL": "http://www.newswise.com/articles/study-links-heartbeat-to-female-libido", "text": "['<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Women with below average HRV were significantly more likely to report sexual arousal dysfunction (p \\\\ .001) and overall sexual dysfunction (p \\\\ .001) than both women with average HRV and women with above average HRV. In conclusion, low HRV may be a risk factor for female sexual arousal dysfunction and overall sexual dysfunction. Given these findings, it is reasonable to expect ANS activity (indexed by HRV) may be related to women\\'s self-reported, real-life sexual arousal function outside of the laboratory.\"><b>Finding:</b></span> In conclusion, low HRV may be a risk factor for female sexual arousal dysfunction and overall sexual dysfunction.']", "displayed_text": "<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Women with below average HRV were significantly more likely to report sexual arousal dysfunction (p \\ .001) and overall sexual dysfunction (p \\ .001) than both women with average HRV and women with above average HRV. In conclusion, low HRV may be a risk factor for female sexual arousal dysfunction and overall sexual dysfunction. Given these findings, it is reasonable to expect ANS activity (indexed by HRV) may be related to women's self-reported, real-life sexual arousal function outside of the laboratory.\"><b>Finding:</b></span> In conclusion, low HRV may be a risk factor for female sexual arousal dysfunction and overall sexual dysfunction."}, "Medicine_tweet_13_r": {"DOI": "10.1002/cncr.30564", "id": "Medicine_tweet_13_r", "News Finding": "Diagnosis and treatment of #oralcancer are assoc w/ changes in sexual behavior, regardless of tumor #HPV status  ", "Paper Finding": "Significant declines in the frequency of vaginal and oral sexual behaviors were reported at follow-up, regardless of tumor HPV status.", "News Context": "Diagnosis and treatment of #oralcancer are assoc w/ changes in sexual behavior, regardless of tumor #HPV status  ", "Paper Context": "Concern over sexual, but not nonsexual, HPV transmission to partners was reported by 50%. Significant declines in the frequency of vaginal and oral sexual behaviors were reported at follow-up, regardless of tumor HPV status. From baseline to 6 months, significant increases in abstinence from vaginal sex (from 10% to 34%; P <.01) and oral sex (from 25% to 80%; P <.01) were reported.", "scores": "[5.0, 2.0, 1.0, 3.0, 5.0]", "field": "Medicine", "split": "val", "final_score": 5.0, "source": "tweets", "News URL": "834783376150249472", "text": "['<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Diagnosis and treatment of #oralcancer are assoc w/ changes in sexual behavior, regardless of tumor #HPV status  \"><b>Finding:</b></span> Diagnosis and treatment of #oralcancer are assoc w/ changes in sexual behavior, regardless of tumor #HPV status  ']", "displayed_text": "<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Diagnosis and treatment of #oralcancer are assoc w/ changes in sexual behavior, regardless of tumor #HPV status  \"><b>Finding:</b></span> Diagnosis and treatment of #oralcancer are assoc w/ changes in sexual behavior, regardless of tumor #HPV status  "}, "test_question_testing_Explicitly states: no relation": {"id": "test_question_testing_Explicitly states: no relation", "text": "<b>Reported Finding:</b> Exposure to traffic noise at the office increases stress levels. This is a test question, please select Explicitly states: no relation. Do not mark any words or phrases.", "displayed_text": "<b>Reported Finding:</b> Exposure to traffic noise at the office increases stress levels. This is a test question, please select Explicitly states: no relation. Do not mark any words or phrases."}, "Medicine_tweet_13_p": {"DOI": "10.1002/cncr.30564", "id": "Medicine_tweet_13_p", "News Finding": "Diagnosis and treatment of #oralcancer are assoc w/ changes in sexual behavior, regardless of tumor #HPV status  ", "Paper Finding": "Significant declines in the frequency of vaginal and oral sexual behaviors were reported at follow-up, regardless of tumor HPV status.", "News Context": "Diagnosis and treatment of #oralcancer are assoc w/ changes in sexual behavior, regardless of tumor #HPV status  ", "Paper Context": "Concern over sexual, but not nonsexual, HPV transmission to partners was reported by 50%. Significant declines in the frequency of vaginal and oral sexual behaviors were reported at follow-up, regardless of tumor HPV status. From baseline to 6 months, significant increases in abstinence from vaginal sex (from 10% to 34%; P <.01) and oral sex (from 25% to 80%; P <.01) were reported.", "scores": "[5.0, 2.0, 1.0, 3.0, 5.0]", "field": "Medicine", "split": "val", "final_score": 5.0, "source": "tweets", "News URL": "834783376150249472", "text": "['<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Concern over sexual, but not nonsexual, HPV transmission to partners was reported by 50%. Significant declines in the frequency of vaginal and oral sexual behaviors were reported at follow-up, regardless of tumor HPV status. From baseline to 6 months, significant increases in abstinence from vaginal sex (from 10% to 34%; P <.01) and oral sex (from 25% to 80%; P <.01) were reported.\"><b>Finding:</b></span> Significant declines in the frequency of vaginal and oral sexual behaviors were reported at follow-up, regardless of tumor HPV status.']", "displayed_text": "<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Concern over sexual, but not nonsexual, HPV transmission to partners was reported by 50%. Significant declines in the frequency of vaginal and oral sexual behaviors were reported at follow-up, regardless of tumor HPV status. From baseline to 6 months, significant increases in abstinence from vaginal sex (from 10% to 34%; P <.01) and oral sex (from 25% to 80%; P <.01) were reported.\"><b>Finding:</b></span> Significant declines in the frequency of vaginal and oral sexual behaviors were reported at follow-up, regardless of tumor HPV status."}, "Medicine_56_r": {"DOI": "10.1001/jama.2014.15690", "id": "Medicine_56_r", "News Finding": "At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent).", "Paper Finding": "The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54).", "News Context": "The researchers found that there was no statistically significant difference between the two groups in time to the primary end point (a composite of death from cardiovascular causes, nonfatal stroke, and nonfatal heart attack). At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent). Aspirin significantly reduced incidence of nonfatal heart attack and transient ischemic attack, and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization.", "Paper Context": "Patients with an occurrence of nonfatal stroke totaled 114 in the aspirin group and 108 in the no aspirin group; of nonfatal myocardial infarction, 20 in the aspirin group and 38 in the no aspirin group; of undefined cerebrovascular events, 3 in the aspirin group and 5 in the no aspirin group. The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54). Aspirin significantly reduced incidence of nonfatal myocardial infarction (0.30 [95% CI, 0.19-0.47] for aspirin vs 0.58 [95% CI, 0.42-0.81] for no aspirin; HR, 0.53 [95% CI, 0.31-0.91]; P = .02) and transient ischemic attack (0.26 [95% CI, 0.16-0.42] for aspirin vs 0.49 [95% CI, 0.35-0.69] for no aspirin; HR, 0.57 [95% CI, 0.32-0.99]; P = .04), and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization (0.86 [95% CI, 0.67-1.11] for aspirin vs 0.51 [95% CI, 0.37-0.72] for no aspirin; HR, 1.85 [95% CI, 1.22-2.81]; P = .004).", "scores": "[5.0, 5.0, 4.0, 5.0]", "field": "Medicine", "split": "train", "final_score": 4.75, "source": "news", "News URL": "http://www.newswise.com/articles/effect-of-once-daily-low-dose-aspirin-on-cv-death-and-other-outcomes", "text": "['<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: The researchers found that there was no statistically significant difference between the two groups in time to the primary end point (a composite of death from cardiovascular causes, nonfatal stroke, and nonfatal heart attack). At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent). Aspirin significantly reduced incidence of nonfatal heart attack and transient ischemic attack, and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization.\"><b>Finding:</b></span> At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent).']", "displayed_text": "<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: The researchers found that there was no statistically significant difference between the two groups in time to the primary end point (a composite of death from cardiovascular causes, nonfatal stroke, and nonfatal heart attack). At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent). Aspirin significantly reduced incidence of nonfatal heart attack and transient ischemic attack, and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization.\"><b>Finding:</b></span> At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent)."}, "test_question_testing_Correlation": {"id": "test_question_testing_Correlation", "text": "<b>Reported Finding:</b> Exposure to traffic noise at the office increases stress levels. This is a test question, please select Correlation. Do not mark any words or phrases.", "displayed_text": "<b>Reported Finding:</b> Exposure to traffic noise at the office increases stress levels. This is a test question, please select Correlation. Do not mark any words or phrases."}, "Medicine_56_p": {"DOI": "10.1001/jama.2014.15690", "id": "Medicine_56_p", "News Finding": "At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent).", "Paper Finding": "The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54).", "News Context": "The researchers found that there was no statistically significant difference between the two groups in time to the primary end point (a composite of death from cardiovascular causes, nonfatal stroke, and nonfatal heart attack). At 5 years after randomization, the cumulative primary event rate was similar in participants in the aspirin group (2.77 percent) and those in the no aspirin group (2.96 percent). Aspirin significantly reduced incidence of nonfatal heart attack and transient ischemic attack, and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization.", "Paper Context": "Patients with an occurrence of nonfatal stroke totaled 114 in the aspirin group and 108 in the no aspirin group; of nonfatal myocardial infarction, 20 in the aspirin group and 38 in the no aspirin group; of undefined cerebrovascular events, 3 in the aspirin group and 5 in the no aspirin group. The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54). Aspirin significantly reduced incidence of nonfatal myocardial infarction (0.30 [95% CI, 0.19-0.47] for aspirin vs 0.58 [95% CI, 0.42-0.81] for no aspirin; HR, 0.53 [95% CI, 0.31-0.91]; P = .02) and transient ischemic attack (0.26 [95% CI, 0.16-0.42] for aspirin vs 0.49 [95% CI, 0.35-0.69] for no aspirin; HR, 0.57 [95% CI, 0.32-0.99]; P = .04), and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization (0.86 [95% CI, 0.67-1.11] for aspirin vs 0.51 [95% CI, 0.37-0.72] for no aspirin; HR, 1.85 [95% CI, 1.22-2.81]; P = .004).", "scores": "[5.0, 5.0, 4.0, 5.0]", "field": "Medicine", "split": "train", "final_score": 4.75, "source": "news", "News URL": "http://www.newswise.com/articles/effect-of-once-daily-low-dose-aspirin-on-cv-death-and-other-outcomes", "text": "['<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Patients with an occurrence of nonfatal stroke totaled 114 in the aspirin group and 108 in the no aspirin group; of nonfatal myocardial infarction, 20 in the aspirin group and 38 in the no aspirin group; of undefined cerebrovascular events, 3 in the aspirin group and 5 in the no aspirin group. The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54). Aspirin significantly reduced incidence of nonfatal myocardial infarction (0.30 [95% CI, 0.19-0.47] for aspirin vs 0.58 [95% CI, 0.42-0.81] for no aspirin; HR, 0.53 [95% CI, 0.31-0.91]; P = .02) and transient ischemic attack (0.26 [95% CI, 0.16-0.42] for aspirin vs 0.49 [95% CI, 0.35-0.69] for no aspirin; HR, 0.57 [95% CI, 0.32-0.99]; P = .04), and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization (0.86 [95% CI, 0.67-1.11] for aspirin vs 0.51 [95% CI, 0.37-0.72] for no aspirin; HR, 1.85 [95% CI, 1.22-2.81]; P = .004).\"><b>Finding:</b></span> The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54).']", "displayed_text": "<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Patients with an occurrence of nonfatal stroke totaled 114 in the aspirin group and 108 in the no aspirin group; of nonfatal myocardial infarction, 20 in the aspirin group and 38 in the no aspirin group; of undefined cerebrovascular events, 3 in the aspirin group and 5 in the no aspirin group. The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54). Aspirin significantly reduced incidence of nonfatal myocardial infarction (0.30 [95% CI, 0.19-0.47] for aspirin vs 0.58 [95% CI, 0.42-0.81] for no aspirin; HR, 0.53 [95% CI, 0.31-0.91]; P = .02) and transient ischemic attack (0.26 [95% CI, 0.16-0.42] for aspirin vs 0.49 [95% CI, 0.35-0.69] for no aspirin; HR, 0.57 [95% CI, 0.32-0.99]; P = .04), and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization (0.86 [95% CI, 0.67-1.11] for aspirin vs 0.51 [95% CI, 0.37-0.72] for no aspirin; HR, 1.85 [95% CI, 1.22-2.81]; P = .004).\"><b>Finding:</b></span> The 5-year cumulative primary outcome event rate was not significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 [95% CI, 0.77-1.15]; P = .54)."}, "Medicine_tweet_68_r": {"DOI": "10.1001/jamapediatrics.2018.0302", "id": "Medicine_tweet_68_r", "News Finding": "#Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. ", "Paper Finding": "Late vitamin D supplementation (initiation at \u226520 weeks' gestation) improved birth weight, but early supplementation (initiation at <20 weeks' gestation) did not.", "News Context": "#Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. ", "Paper Context": "We found that maternal vitamin D supplementation timing, dose, and administration method did not affect cord blood vitamin D concentration. Late vitamin D supplementation (initiation at \u226520 weeks' gestation) improved birth weight, but early supplementation (initiation at <20 weeks' gestation) did not. Most importantly, we found that the lower dose of vitamin D supplementation (\u22642000 IU/d) reduced the risk of fetal or neonatal mortality and SGA, but the higher dose (>2000 IU/d) did not.", "scores": "[4.0, 2.0, 5.0, 2.0]", "field": "Medicine", "split": "train", "final_score": 4.0, "source": "tweets", "News URL": "1001559206733012993", "text": "['<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: #Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. \"><b>Finding:</b></span> #Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. ']", "displayed_text": "<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: #Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. \"><b>Finding:</b></span> #Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. "}, "Medicine_tweet_68_p": {"DOI": "10.1001/jamapediatrics.2018.0302", "id": "Medicine_tweet_68_p", "News Finding": "#Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. ", "Paper Finding": "Late vitamin D supplementation (initiation at \u226520 weeks' gestation) improved birth weight, but early supplementation (initiation at <20 weeks' gestation) did not.", "News Context": "#Vitamin D supplementation during #pregnancy may reduce the risk for underweight babies and fetal or infant mortality. ", "Paper Context": "We found that maternal vitamin D supplementation timing, dose, and administration method did not affect cord blood vitamin D concentration. Late vitamin D supplementation (initiation at \u226520 weeks' gestation) improved birth weight, but early supplementation (initiation at <20 weeks' gestation) did not. Most importantly, we found that the lower dose of vitamin D supplementation (\u22642000 IU/d) reduced the risk of fetal or neonatal mortality and SGA, but the higher dose (>2000 IU/d) did not.", "scores": "[4.0, 2.0, 5.0, 2.0]", "field": "Medicine", "split": "train", "final_score": 4.0, "source": "tweets", "News URL": "1001559206733012993", "text": "['<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: We found that maternal vitamin D supplementation timing, dose, and administration method did not affect cord blood vitamin D concentration. Late vitamin D supplementation (initiation at \u226520 weeks\\' gestation) improved birth weight, but early supplementation (initiation at <20 weeks\\' gestation) did not. Most importantly, we found that the lower dose of vitamin D supplementation (\u22642000 IU/d) reduced the risk of fetal or neonatal mortality and SGA, but the higher dose (>2000 IU/d) did not.\"><b>Finding:</b></span> Late vitamin D supplementation (initiation at \u226520 weeks\\' gestation) improved birth weight, but early supplementation (initiation at <20 weeks\\' gestation) did not.']", "displayed_text": "<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: We found that maternal vitamin D supplementation timing, dose, and administration method did not affect cord blood vitamin D concentration. Late vitamin D supplementation (initiation at \u226520 weeks' gestation) improved birth weight, but early supplementation (initiation at <20 weeks' gestation) did not. Most importantly, we found that the lower dose of vitamin D supplementation (\u22642000 IU/d) reduced the risk of fetal or neonatal mortality and SGA, but the higher dose (>2000 IU/d) did not.\"><b>Finding:</b></span> Late vitamin D supplementation (initiation at \u226520 weeks' gestation) improved birth weight, but early supplementation (initiation at <20 weeks' gestation) did not."}, "Medicine_71_r": {"DOI": "10.1136/annrheumdis-2013-203804", "id": "Medicine_71_r", "News Finding": "Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it's a common condition.", "Paper Finding": "The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%).", "News Context": "With 19 years of follow-up, Chingford is far and away the largest and longest longitudinal study of first MTP joint OA. Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it's a common condition. The first MTP joint was the most commonly affected site, with a prevalence of 7.8%, followed by the second cuneometatarsal joint (CMJ) at 6.8%, the talonavicular joint (TNJ) at 5.2%, the navicular first cuneiform joint (NCJ) at 5.2%, and the first CMJ at 3.9%.", "Paper Context": "Population prevalence of symptomatic radiographic foot OA Population prevalence estimates were almost identical in the baseline responder population and the total baseline eligible mailed population, hence the latter data are presented. The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%). The most commonly affected joint was the 1st MTPJ (7.8%; 95% CI 6.7% to 8.9%), followed by the 2nd CMJ (6.8%; 95% CI 5.7% to 7.8%), TNJ (5.8%; 95% CI 4.8% to 6.9%), NCJ (5.2%; 95% CI 4.0% to 6.4%) and 1st CMJ (3.9%; 95% CI 2.9% to 4.9%) (table 3) .", "scores": "[4.0, 5.0, 4.0, 4.0]", "field": "Medicine", "split": "test", "final_score": 4.25, "source": "news", "News URL": "http://ct.moreover.com/?a=39498153871&p=1pl&v=1&x=ABngbXsk5KufxyHrE-m2mg", "text": "['<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: With 19 years of follow-up, Chingford is far and away the largest and longest longitudinal study of first MTP joint OA. Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it\\'s a common condition. The first MTP joint was the most commonly affected site, with a prevalence of 7.8%, followed by the second cuneometatarsal joint (CMJ) at 6.8%, the talonavicular joint (TNJ) at 5.2%, the navicular first cuneiform joint (NCJ) at 5.2%, and the first CMJ at 3.9%.\"><b>Finding:</b></span> Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it\\'s a common condition.']", "displayed_text": "<span id=\"hover_text_news\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: With 19 years of follow-up, Chingford is far and away the largest and longest longitudinal study of first MTP joint OA. Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it's a common condition. The first MTP joint was the most commonly affected site, with a prevalence of 7.8%, followed by the second cuneometatarsal joint (CMJ) at 6.8%, the talonavicular joint (TNJ) at 5.2%, the navicular first cuneiform joint (NCJ) at 5.2%, and the first CMJ at 3.9%.\"><b>Finding:</b></span> Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it's a common condition."}, "Medicine_71_p": {"DOI": "10.1136/annrheumdis-2013-203804", "id": "Medicine_71_p", "News Finding": "Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it's a common condition.", "Paper Finding": "The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%).", "News Context": "With 19 years of follow-up, Chingford is far and away the largest and longest longitudinal study of first MTP joint OA. Among the 557 symptomatic participants with foot x-rays, the prevalence of radiographic OA of the foot was 16.7%, or roughly one in six - underscoring that it's a common condition. The first MTP joint was the most commonly affected site, with a prevalence of 7.8%, followed by the second cuneometatarsal joint (CMJ) at 6.8%, the talonavicular joint (TNJ) at 5.2%, the navicular first cuneiform joint (NCJ) at 5.2%, and the first CMJ at 3.9%.", "Paper Context": "Population prevalence of symptomatic radiographic foot OA Population prevalence estimates were almost identical in the baseline responder population and the total baseline eligible mailed population, hence the latter data are presented. The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%). The most commonly affected joint was the 1st MTPJ (7.8%; 95% CI 6.7% to 8.9%), followed by the 2nd CMJ (6.8%; 95% CI 5.7% to 7.8%), TNJ (5.8%; 95% CI 4.8% to 6.9%), NCJ (5.2%; 95% CI 4.0% to 6.4%) and 1st CMJ (3.9%; 95% CI 2.9% to 4.9%) (table 3) .", "scores": "[4.0, 5.0, 4.0, 4.0]", "field": "Medicine", "split": "test", "final_score": 4.25, "source": "news", "News URL": "http://ct.moreover.com/?a=39498153871&p=1pl&v=1&x=ABngbXsk5KufxyHrE-m2mg", "text": "['<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Population prevalence of symptomatic radiographic foot OA Population prevalence estimates were almost identical in the baseline responder population and the total baseline eligible mailed population, hence the latter data are presented. The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%). The most commonly affected joint was the 1st MTPJ (7.8%; 95% CI 6.7% to 8.9%), followed by the 2nd CMJ (6.8%; 95% CI 5.7% to 7.8%), TNJ (5.8%; 95% CI 4.8% to 6.9%), NCJ (5.2%; 95% CI 4.0% to 6.4%) and 1st CMJ (3.9%; 95% CI 2.9% to 4.9%) (table 3) .\"><b>Finding:</b></span> The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%).']", "displayed_text": "<span id=\"hover_text_paper\" data-toggle=\"tooltip\" data-html=\"true\" data-placement=\"bottom\" title=\"Context: Population prevalence of symptomatic radiographic foot OA Population prevalence estimates were almost identical in the baseline responder population and the total baseline eligible mailed population, hence the latter data are presented. The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%). The most commonly affected joint was the 1st MTPJ (7.8%; 95% CI 6.7% to 8.9%), followed by the 2nd CMJ (6.8%; 95% CI 5.7% to 7.8%), TNJ (5.8%; 95% CI 4.8% to 6.9%), NCJ (5.2%; 95% CI 4.0% to 6.4%) and 1st CMJ (3.9%; 95% CI 2.9% to 4.9%) (table 3) .\"><b>Finding:</b></span> The population prevalence of symptomatic radiographic foot OA in adults aged 50 years and over was 16.7% (95% CI 15.3% to 18.0%)."}, "Experience.html": {"id": "Experience.html", "text": "Experience", "displayed_text": "Experience"}, "End.html": {"id": "End.html", "text": "End", "displayed_text": "End"}}